KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Halozyme Therapeutics (HALO) over the last 13 years, with Q4 2025 value amounting to $113.9 million.

  • Halozyme Therapeutics' Other Non-Current Liabilities rose 10793.86% to $113.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $113.9 million, marking a year-over-year increase of 10793.86%. This contributed to the annual value of $113.9 million for FY2025, which is 10793.86% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Other Non-Current Liabilities stood at $113.9 million for Q4 2025, which was up 10793.86% from $71.8 million recorded in Q3 2025.
  • Halozyme Therapeutics' Other Non-Current Liabilities' 5-year high stood at $130.0 million during Q2 2022, with a 5-year trough of $171000.0 in Q1 2022.
  • For the 5-year period, Halozyme Therapeutics' Other Non-Current Liabilities averaged around $45.2 million, with its median value being $31.9 million (2022).
  • In the last 5 years, Halozyme Therapeutics' Other Non-Current Liabilities plummeted by 9391.24% in 2022 and then surged by 1719415.2% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Other Non-Current Liabilities stood at $544000.0 in 2021, then skyrocketed by 5908.46% to $32.7 million in 2022, then increased by 15.4% to $37.7 million in 2023, then surged by 45.17% to $54.8 million in 2024, then skyrocketed by 107.94% to $113.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $113.9 million for Q4 2025, versus $71.8 million for Q3 2025 and $77.8 million for Q2 2025.